Literature DB >> 31179356

Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma.

Bita Moudi1,2, Zahra Heidari1,2, Hamidreza Mahmoudzadeh-Sagheb1,2.   

Abstract

Hepatocellular carcinoma (HCC) is a common malignant cancer and the second cause of cancer-related death worldwide. Glypican-3 (GPC3) is established as an important prognostic factor for HCC but the results are still controversial. Moreover, its utility as an immunohistochemical marker for HCC is not conclusive. Herein we aimed to find the prognostic significance of GPC3 in HCC patients. The PubMed, Web of Science, EMBASE, SCOPUS and Cochrane library databases were searched and eligible studies based on the GPC3 expression and survival outcome of HCC (odds ratios or hazard ratios) included in the current meta-analysis. The STATA 12.0 and RevMan 5.3 software were used for statistical evaluations. 17 articles contained 2618 patients, were included in the recent meta-analysis. Our findings revealed a significant association between tumor stage, higher tumor grade, presence of vascular invasion, shorter overall survival, shorter disease-free survival and high expression of GPC3. The subgroup analyses based on sample size, cutoffs and follow-up period were also conducted to examine the association between GPC3 and OS and also to increase the homogeneity of study. Current study found a significant association between GPC3 expression and poor prognosis of HCC and specially related to the HCC invasion and progression. It was recommended to design more prospective studies based on the relationship between GPC3 and HCC to confirm our results.

Entities:  

Keywords:  GPC3; HCC; Meta-analysis

Year:  2019        PMID: 31179356      PMCID: PMC6531550          DOI: 10.1007/s13337-019-00517-6

Source DB:  PubMed          Journal:  Virusdisease        ISSN: 2347-3584


  52 in total

1.  A comparison of methods to detect publication bias in meta-analysis by P. Macaskill, S. D. Walter and L. Irwig, Statistics in Medicine, 2001; 20:641-654.

Authors:  Colin B Begg
Journal:  Stat Med       Date:  2002-06-30       Impact factor: 2.373

2.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

3.  Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.

Authors:  Xiao Ying Wang; Françoise Degos; Sylvie Dubois; Sandrine Tessiore; Mark Allegretta; Ronald D Guttmann; Serge Jothy; Jacques Belghiti; Pierre Bedossa; Valérie Paradis
Journal:  Hum Pathol       Date:  2006-08-10       Impact factor: 3.466

Review 4.  Glypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma.

Authors:  Baruch D Jakubovic; Serge Jothy
Journal:  Exp Mol Pathol       Date:  2007-01-26       Impact factor: 3.362

Review 5.  Glypicans in growth control and cancer.

Authors:  J Filmus
Journal:  Glycobiology       Date:  2001-03       Impact factor: 4.313

Review 6.  The contribution of in vivo manipulation of gene expression to the understanding of the function of glypicans.

Authors:  Jorge Filmus
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

7.  Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.

Authors:  Louis Libbrecht; Tamara Severi; David Cassiman; Sara Vander Borght; Jacques Pirenne; Frederik Nevens; Chris Verslype; Jos van Pelt; Tania Roskams
Journal:  Am J Surg Pathol       Date:  2006-11       Impact factor: 6.394

8.  Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma.

Authors:  Hu-Liang Jia; Qing-Hai Ye; Lun-Xiu Qin; Anuradha Budhu; Marshonna Forgues; Yidong Chen; Yin-Kun Liu; Hui-Chuan Sun; Lu Wang; Hong-Zhou Lu; Fang Shen; Zhao-You Tang; Xin Wei Wang
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

9.  Glypican 4 modulates FGF signalling and regulates dorsoventral forebrain patterning in Xenopus embryos.

Authors:  Antonella Galli; Agnes Roure; Rolf Zeller; Rosanna Dono
Journal:  Development       Date:  2003-08-20       Impact factor: 6.868

Review 10.  Strategies for the management of hepatocellular carcinoma.

Authors:  Myron Schwartz; Sasan Roayaie; Manousos Konstadoulakis
Journal:  Nat Clin Pract Oncol       Date:  2007-07
View more
  4 in total

1.  Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice.

Authors:  Xiaoxiao Jin; Xiaotao Liu; Zining Zhou; Yan Ding; Yandan Wu; Jie Qiu; Chuanlai Shen
Journal:  Cancer Immunol Immunother       Date:  2021-11-01       Impact factor: 6.968

2.  Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma.

Authors:  Jian-Yao Wang; Xiang-Kun Wang; Guang-Zhi Zhu; Xin Zhou; Jun Yao; Xiao-Peng Ma; Bin Wang; Tao Peng
Journal:  BMC Cancer       Date:  2021-04-26       Impact factor: 4.430

3.  Hepatocyte paraffin 1 and arginase-1 are effective panel of markers in HBV-related HCC diagnosis in fine-needle aspiration specimens.

Authors:  Bita Moudi; Hamidreza Mahmoudzadeh-Sagheb; Zahra Heidari
Journal:  BMC Res Notes       Date:  2020-08-20

4.  A poor prognosis in human hepatocellular carcinoma is associated with low expression of DPP4.

Authors:  Hao Yu; Xiao-Ping Mei; Peng-Fei Su; Guang-Zhi Jin; Hong-Kun Zhou
Journal:  Braz J Med Biol Res       Date:  2020-04-09       Impact factor: 2.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.